- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03936257
Effect of an Innovative BIO Formula Intake on Infant Growth and Tolerance From 0 to 6 Months (TRUEGREEN)
Evaluation of an Innovative BIO Formula Based on a New Whey Extraction Process on the Growth and Tolerance of Infants From 0 to 6 Months.
From birth to 5 months, milk is the essential and unique food of the newborn. The French National Nutrition Program (PNNS) recommends exclusive breastfeeding "up to 6 months and at least 4 months for a healthy benefit". However, only 36% of infants 0-6 months of age are exclusively breastfed worldwide. Some mothers choose to give infant formula to their baby in the first few months of life. This decision may be a personal choice or be imposed by pathophysiological situations.
The nutritional requirements of the infant are specific, which implies adequate nutrition. Infant formulas and follow-up formulas are therefore complex products, specially developed for a group of vulnerable consumers. In fact, the compositional and information requirements for infant formula are highly regulated.
This study, defined as a pilot study, proposes to evaluate the innovative "TrueGreen" BIO infant formula based on a new whey extraction method on the growth and tolerance of infants from 0 to 6 months compared to the conventional BIO infant formula. As no growth and tolerance data are currently available for this new TrueGreen BIO formula, this study aims to determine them.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Nord
-
Lille, Nord, Ranska, 59019
- NutrInvest - Institut Pasteur de Lille
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- 0 to 3 weeks
- Child followed by a general practitioner or pediatrician
- Informed consent form signed by the legal representatives of the subject
- Commitment of legal representatives to follow the constraints generated by the study
- Insured
Exclusion Criteria:
- Infant born prematurely before 37 weeks of amenorrhea
- Child allergic to cow's milk proteins
- Pathological pregnancy (hypertension, infection, gestational diabetes, etc.);
- Chronic or acute illness (metabolic or neuromuscular diseases, epilepsy, asthma, diabetes, digestive, renal, cardiac or haematological diseases);
- Incapacity for the legal representative(s) to understand or adhere to the protocol
- Subject involved in another clinical study or in an exclusion period from another study
- Legal representatives deprived of liberty
- Legal representatives in a position to judicial protection
- Weight of the subject according to age and sex, not included between the 3rd and the 97th percentile of the WHO Child Growth Standards
- Subject height according to age and sex, not between the 3rd and the 97th percentile of the WHO Child Growth Standards
- BMI of the subject according to age and sex, not included between the 3rd and the 97th percentile of the WHO Child Growth Standards
- Head circumference of the subject according to age and sex, not included between the 3rd and the 97th percentile of the WHO (World Health Organization) Child Growth Standards
- The investigator considers that the state of health or the concomitant treatments are not compatible with the good progress of the clinical study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Placebo Comparator: Breast milk
group receiving breastfeeding
|
Infants were breastfed during 3 months minimum.
Data on growth and tolerance were collected.
10 out of 40 infants take a blood test to metabolome analysis
|
Active Comparator: infant formula conventional BIO
infant formula with conventional whey BIO
|
Infant were fed during 6 months with a conventional BIO infant formula.
Data on growth and tolerance were collected.
10 out of 40 infants take a blood test to metabolome analysis
|
Active Comparator: infant formula BIO TrueGreen
infant formula with whey BIO TrueGreen
|
Infant were fed during 6 months with the TrueGreen BIO infant formula.
Data on growth and tolerance were collected.
10 out of 40 infants take a blood test to metabolome analysis
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Evolution of growth of infants
Aikaikkuna: from 0 to 6 months
|
Weight in kilograms
|
from 0 to 6 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Height evolution of infants
Aikaikkuna: from 0 to 6 months
|
data in centimeters
|
from 0 to 6 months
|
BMI evolution of infants
Aikaikkuna: from 0 to 6 months
|
data in kg/m²
|
from 0 to 6 months
|
Head circumference evolution of infants
Aikaikkuna: from 0 to 6 months
|
data in centimeters
|
from 0 to 6 months
|
Number of colic per day
Aikaikkuna: from 0 to 6 months
|
Evaluation during 3 consecutives days every month.
|
from 0 to 6 months
|
Consistency of stool
Aikaikkuna: from 0 to 6 months
|
Evaluation during 3 consecutive days every month via Bristol scale. According to the bristol scale, seven types of stool are considered: Type 1: Separate hard lumps, like nuts (hard to pass) Type 2: Sausage-shaped, but lumpy Type 3: Like a sausage but with cracks on its surface Type 4: Like a sausage or snake, smooth and soft Type 5: Soft blobs with clear cut edges (easy to pass) Type 6: Fluffy pieces with ragged edges, a mushy stool Type 7: Watery, no solid pieces, entirely liquid The mean of stool type during 3 days is considered. |
from 0 to 6 months
|
Number of regurgitation
Aikaikkuna: from 0 to 6 months
|
Evaluation during 3 consecutive days every month via Vandenplas scale. According to the Vandenplas scale, seven score are considered: 0 0-2 episodes/day
The mean of score during 3 days is considered. |
from 0 to 6 months
|
Number of wake up per night
Aikaikkuna: from 0 to 6 months
|
Evaluation during 3 consecutive days every month.
|
from 0 to 6 months
|
Total sleep time per day
Aikaikkuna: from 0 to 6 months
|
Time in hours.
Evaluation during 3 consecutive days every month.
|
from 0 to 6 months
|
Plasma amino acid profile
Aikaikkuna: between 3rd and 4th month
|
Methods : Liquid Chromatography and Tandem Mass Spectrometry (LC / MS / MS) List of amino acids : Taurine, Aspartic acid, Threonine, Serine, Asparagine, Glutamine acid, Glutamine, Glycine, Alanine, Citrulline, Valine, Cystine, Methionine, Isoleucine, Leucine, Tyrosine, Phenylalanine, Beta aminoisobutyric acid, Ornithine, 1-Methyl-Histidine, Histidine, Lysine, 3-methyl-Histidine, Arginine, Hydroxyproline, Proline
|
between 3rd and 4th month
|
Metabolomic analysis from plasma and urine samples
Aikaikkuna: between 3rd and 4th month
|
Non-targeted analysis : evaluation of all small molecules in biological system, such as amino acids, sugars, alcohols, sugar phosphates, amines, fatty acids, polar lipids, hormones and vitamins, as well as specialized metabolites, such as phenolic compounds, flavonoids, monoterpenes, sesquiterpenes, polyketides, alkaloids, including xenobiotics. Methods : Liquid Chromatography and Mass Spectrometry (LC / MS) |
between 3rd and 4th month
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- 2018-A00732-53
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Lapsen kehitys
-
MedDay Pharmaceuticals SAEurofins OptimedLopetettuTerveet vapaaehtoiset | Keskivaikean Child Pugh -kategorian maksan vajaatoimintaRanska, Unkari
-
Johns Hopkins Bloomberg School of Public HealthValmisEarly Childhood Development (ECD)
-
RenJi HospitalValmisVerihiutaleiden määrän/pernan halkaisijan suhde | Child-Pugh-luokitusKiina
-
Stanford UniversityNational Cancer Institute (NCI)LopetettuToistuva hepatosellulaarinen karsinooma | Child-Pugh luokka A | Child-Pugh luokka BYhdysvallat, Japani
-
Ohio State University Comprehensive Cancer CenterVarian Medical SystemsValmisChild-Pugh luokka A | Vaihe IIIA Maksasolukarsinooma | Vaiheen IIIB maksasolusyöpä | Vaiheen IIIC hepatosellulaarinen karsinooma | IVA-vaiheen hepatosellulaarinen karsinooma | Vaihe IVB hepatosellulaarinen karsinooma | Child-Pugh luokka BYhdysvallat
-
Centre Hospitalier Universitaire DijonValmisChild-Pugh: MaksasolusyöpäRanska
-
The University of New South WalesNational Health and Medical Research Council, Australia; Novo Nordisk A/S; Sydney Children's Hospitals NetworkValmisTyypin 1 diabetes | Murrosikä: >Tanner 2 Breast Development tai kivekset >4mlAustralia
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCAktiivinen, ei rekrytointiPitkälle edennyt aikuisten hepatosellulaarinen syöpä | Child-Pugh luokka A | Vaiheen III hepatosellulaarinen karsinooma | Vaihe IIIA Maksasolukarsinooma | Vaiheen IIIB maksasolusyöpä | Vaiheen IIIC hepatosellulaarinen karsinooma | IV vaiheen hepatosellulaarinen karsinooma | IVA-vaiheen hepatosellulaarinen... ja muut ehdotYhdysvallat
-
AstraZenecaLopetettuMahasyöpä | Pitkälle edenneet kiinteät pahanlaatuiset kasvaimet | Kiinteä kasvain | Edistynyt Child-Pugh A - B7 hepatosellulaarinen karsinooma | EGFR ja/tai ROS-mutantti NSCLC | Keuhkojen metastaasikarsinoomaKorean tasavalta